stoxline Quote Chart Rank Option Currency Glossary
  
Akari Therapeutics, Plc (AKTX)
1.205  0.105 (9.55%)    04-17 16:00
Open: 1.1
High: 1.2799
Volume: 17,294
  
Pre. Close: 1.1
Low: 1.1
Market Cap: 0(M)
Technical analysis
2025-04-17 4:47:05 PM
Short term     
Mid term     
Targets 6-month :  1.66 1-year :  2.02
Resists First :  1.42 Second :  1.73
Pivot price 1.15
Supports First :  0.93 Second :  0.77
MAs MA(5) :  1.13 MA(20) :  1.21
MA(100) :  1.13 MA(250) :  2.1
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  41.6 D(3) :  28.3
RSI RSI(14): 52.6
52-week High :  4.4 Low :  0.85
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AKTX ] has closed below upper band by 27.8%. Bollinger Bands are 63% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.28 - 1.29 1.29 - 1.29
Low: 1.09 - 1.09 1.09 - 1.1
Close: 1.19 - 1.2 1.2 - 1.21
Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Headline News

Thu, 17 Apr 2025
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks

Wed, 16 Apr 2025
Akari Therapeutics PLC Reports $21.6 Million Net Loss for 2024 Amid Strategic ADC Development Focus - GuruFocus

Wed, 16 Apr 2025
Akari Therapeutics Cash On Hand Expected To Be Sufficient To Fund Planned Operations Into September 2025 - marketscreener.com

Wed, 16 Apr 2025
Akari Therapeutics (AKTX) Poised for Growth After Completing Merger with Peak Bio | AKTX Stock News - GuruFocus

Wed, 16 Apr 2025
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Wed, 16 Apr 2025
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 26 (M)
Shares Float 19,790 (M)
Held by Insiders 44.7 (%)
Held by Institutions 1.3 (%)
Shares Short 86 (K)
Shares Short P.Month 78 (K)
Stock Financials
EPS -2.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.56
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.66
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.47
PEG Ratio 0
Price to Book value -2.2
Price to Sales 0
Price to Cash Flow -2.15
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android